Literature DB >> 7882869

Cocaine and crack use and HIV risk behaviors among high-risk methadone maintenance clients.

C E Grella1, M D Anglin, S E Wugalter.   

Abstract

A discriminant function analysis was performed with data from 409 high-risk heroin addicts at intake into a methadone maintenance treatment program to determine the characteristics of cocaine users. Cocaine users presented a higher-risk profile for human immunodeficiency virus (HIV), engaged in a wider variety of criminal activities, were more likely to be African-American, reported more alcohol use, and showed more signs of psychological disturbance. A second discriminant function analysis determined that crack smokers differed from non-crack cocaine users in ethnicity, alcohol use, criminal activity, needle use, and marital status. Heroin addicts who use cocaine, in particular crack, represent a sub-group at higher risk and in need of targeted treatment planning and monitoring.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7882869     DOI: 10.1016/0376-8716(94)01059-t

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  35 in total

1.  Predicting posttreatment cocaine abstinence for first-time admissions and treatment repeaters.

Authors:  Y I Hser; V Joshi; M D Anglin; B Fletcher
Journal:  Am J Public Health       Date:  1999-05       Impact factor: 9.308

2.  The Massachusetts HIV, hepatitis, addiction services integration (HHASI) experience: responding to the comprehensive needs of individuals with co-occurring risks and conditions.

Authors:  Heidi L Hoffman; Carolyn A Castro-Donlan; Victoria M Johnson; Daniel R Church
Journal:  Public Health Rep       Date:  2004 Jan-Feb       Impact factor: 2.792

3.  Self-administration of cocaine and remifentanil by monkeys: choice between single drugs and mixtures.

Authors:  Kevin B Freeman; William L Woolverton
Journal:  Psychopharmacology (Berl)       Date:  2010-12-30       Impact factor: 4.530

4.  Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment.

Authors:  Jonathan D Savant; Declan T Barry; Christopher J Cutter; Michelle T Joy; An Dinh; Richard S Schottenfeld; David A Fiellin
Journal:  Drug Alcohol Depend       Date:  2012-07-06       Impact factor: 4.492

5.  Factors related to correctional facility incarceration among active injection drug users in Baltimore, MD.

Authors:  Stevan Geoffrey Severtson; William W Latimer
Journal:  Drug Alcohol Depend       Date:  2007-12-21       Impact factor: 4.492

6.  Risk factors in the relationship between gender and crack/cocaine.

Authors:  C W Lejuez; Marina A Bornovalova; Elizabeth K Reynolds; Stacey B Daughters; John J Curtin
Journal:  Exp Clin Psychopharmacol       Date:  2007-04       Impact factor: 3.157

7.  Cocaine administration dose-dependently increases sexual desire and decreases condom use likelihood: The role of delay and probability discounting in connecting cocaine with HIV.

Authors:  Matthew W Johnson; Evan S Herrmann; Mary M Sweeney; Robert S LeComte; Patrick S Johnson
Journal:  Psychopharmacology (Berl)       Date:  2016-12-05       Impact factor: 4.530

8.  Comparable efficacy of contingency management for cocaine dependence among African American, Hispanic, and White methadone maintenance clients.

Authors:  Danielle Barry; Brendan Sullivan; Nancy M Petry
Journal:  Psychol Addict Behav       Date:  2009-03

9.  Self-administration of cocaine and remifentanil by monkeys under concurrent-access conditions.

Authors:  Sally L Huskinson; Kevin B Freeman; William L Woolverton
Journal:  Psychopharmacology (Berl)       Date:  2014-06-26       Impact factor: 4.530

10.  Cocaine-dependent adults and recreational cocaine users are more likely than controls to choose immediate unsafe sex over delayed safer sex.

Authors:  Mikhail N Koffarnus; Matthew W Johnson; Daisy G Y Thompson-Lake; Michael J Wesley; Terry Lohrenz; P Read Montague; Warren K Bickel
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.